Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Making hearing aids free for seniors could prevent more dementia cases than any drug currently in development because hearing loss is the single largest modifiable risk factor for dementia—and the evidence shows that treating it actually works. When 28 million Americans could benefit from hearing aids but 86% of people over 50 with hearing loss don’t use them, the barrier isn’t biology or brain disease progression. It’s cost. A pair of prescription hearing aids averages $2,300 to $4,000, with zero Medicare coverage. Meanwhile, the research keeps accumulating: a recent University of Southern Denmark study of over 573,000 people found hearing loss increases dementia risk by 7%, and treating it with hearing aids reduced that risk significantly. No dementia drug on the horizon shows this kind of preventive power in real-world populations.
The contrast is striking because it exposes a gap in how we think about dementia prevention. We pour billions into pharmaceutical research for drugs that might slow cognitive decline by months or extend someone’s disease-free years by a few years. But we’ve largely overlooked a non-drug intervention—hearing aids—that the 2024 Lancet Commission on dementia prevention identified as one of the most impactful modifiable risk factors available. The ACHIEVE Study, a randomized controlled trial of 977 older adults followed for three years, found that treating hearing loss actually slowed cognitive decline. A 2026 study published in early 2026 showed just 5% of people prescribed hearing aids developed dementia compared to 8% of those without prescriptions. These aren’t marginal improvements. These are meaningful reductions in dementia development that rival what most pharmaceutical interventions promise.
Table of Contents
- How Does Treating Hearing Loss Actually Reduce Dementia Risk?
- Why Hearing Aids Outpace Every Drug in Development for Dementia Prevention
- The Evidence Gets Stronger as We Study Larger Populations
- The Cost Comparison: What Would Free Hearing Aids Actually Cost?
- The Adoption Barrier: Why Free Isn’t Automatic
- Real-World Evidence from Existing Assistance Programs
- What Happens When Hearing Loss Prevention Becomes a Public Health Priority?
- Conclusion
How Does Treating Hearing Loss Actually Reduce Dementia Risk?
The mechanism is simpler than most people expect, but the research is sophisticated. When hearing loss goes untreated, the brain works harder to extract meaning from sound—a process called “listening effort.” Over years, this constant strain on cognitive resources appears to accelerate cognitive aging. The auditory cortex, the area of the brain responsible for processing sound, actually shrinks in people with untreated hearing loss. When you restore hearing with aids, you reduce that cognitive load, and the evidence suggests this slowdown in cognitive decline accumulates over decades. The Framingham Heart Study, one of the largest longitudinal studies of cardiovascular and neurological health, found that patients under 70 with hearing loss who used hearing aids reduced their dementia risk by 61% over 20 years. That’s not a marginal reduction.
But there’s an important caveat: the benefit emerges over time, not immediately. A 2026 study found that hearing aids did not improve performance on short-term memory or cognitive thinking tests. What changed was the longer trajectory—people on hearing aids developed dementia at lower rates over years of follow-up. This matters because it suggests hearing aids work not by boosting brain function directly, but by reducing the cumulative damage of chronic cognitive strain. Johns Hopkins research found that among people with moderate to severe hearing loss, those using hearing aids had 32% lower prevalence of dementia. The effect size grows with severity: a meta-analysis of 31 studies with over 137,000 participants found that hearing loss increases dementia risk by 8% to 17% depending on how severe the loss is. If you prevent 8-17% of dementia cases in a population, you’ve prevented more cases than any drug currently available.
Why Hearing Aids Outpace Every Drug in Development for Dementia Prevention
Compare this to the dementia drugs currently in clinical trials or being developed. Lecanemab (Leqembi) and donanemab, monoclonal antibodies targeting amyloid, show slowing of cognitive decline by roughly 35% over 18 months in early-stage Alzheimer’s disease. That sounds impressive until you notice the fine print: they work in a narrow population (early cognitive impairment, confirmed amyloid pathology), they require infusions every few weeks, they cost tens of thousands of dollars annually, and they come with serious risks including amyloid-related imaging abnormalities that can cause brain inflammation and microhemorrhages. Most dementia drugs in development are similarly limited: they target a specific biological pathway, they work in a subset of patients with the right biomarkers, they slow disease by months rather than preventing it, and they cost far more than hearing aids. Hearing aids, by contrast, work across the entire spectrum of hearing loss severity. They benefit people whether or not they have amyloid plaques, tau tangles, or any confirmed Alzheimer’s pathology.
They prevent dementia rather than slow it once it starts. And they’re available now, not in a decade after regulatory approval. The practical impact is enormous: if you could get 28 million Americans who could benefit from hearing aids to actually use them, you would prevent far more dementia cases than every drug in development combined could treat. The limitation here is not biological—it’s systemic. Most seniors don’t use hearing aids because they can’t afford them, not because the hearing aids don’t work. The barrier is purely economic.
The Evidence Gets Stronger as We Study Larger Populations
The research supporting hearing aids for dementia prevention isn’t a single study or an outlier finding. It’s a convergence of evidence across multiple large populations and different study designs. The University of Southern Denmark study—the largest to date at 573,088 people—found that hearing loss increases dementia risk by 7%, and critically, hearing aid users had substantially lower dementia incidence. The ACHIEVE Study, a randomized controlled trial (the gold standard of study design), assigned 977 older adults to either get hearing treatment or usual care and followed them for three years. The result: treating hearing loss slowed cognitive decline. This wasn’t an observational study where people who use hearing aids happen to be healthier overall. It was a randomized trial where hearing treatment was the intervention.
The Lancet Commission, which reviewed decades of research on modifiable dementia risk factors, ranked hearing loss as the largest potentially modifiable risk factor for dementia across the lifespan. Not one of many. The largest. Yet the adoption rate remains abysmal: only 14% of Americans over 50 with hearing loss actually use hearing aids, and only 30% of Americans 70 and older with hearing loss have ever tried them. This gap between what the science shows and what people actually do is where policy could make an enormous difference. If making hearing aids free increased adoption rates from 14% to even 40% among over-50 adults with hearing loss, the dementia prevention benefit would dwarf what any pharmaceutical intervention could achieve. The limitation: we don’t have perfect data yet on whether universal free hearing aids would change adoption rates as dramatically as we’d hope, though programs like the VA (which provides free hearing aids to veterans) and state Medicaid programs suggest free or heavily subsidized devices do increase usage.
The Cost Comparison: What Would Free Hearing Aids Actually Cost?
The financial case for making hearing aids free is deceptively straightforward. Prescription hearing aids cost an average of $2,300 per device or $1,000 to $4,000 per pair. Over-the-counter hearing aids average $1,600 per pair. These are one-time costs (though devices may need replacement every 3-7 years). Compare this to the cost of managing dementia: the average lifetime cost of dementia care per patient in the United States is approximately $290,000 to $370,000 when accounting for direct medical costs, long-term care, and informal caregiver time. One pair of hearing aids might cost $3,000. Dementia care costs 100 times that amount. Even if free hearing aids prevented dementia in just 10% of people who used them, the return on investment would be extraordinary. And the research suggests the benefit is much higher than that.
Here’s the practical tradeoff: a national program to provide free hearing aids to all seniors (ages 65+) with hearing loss would cost perhaps $5 billion to $8 billion annually in device costs and fitting services. The U.S. federal government spends roughly $300 billion annually on Medicare alone, and dementia care consumes an ever-growing portion of that. If a $6 billion investment in free hearing aids prevented even 5% of dementia cases, it would save tens of billions in downstream care costs within a decade. The limiting factor isn’t whether it’s cost-effective. It’s political will and the fact that the hearing aid industry benefits from the current expensive status quo. Device manufacturers would lose margin on budget models, audiologists would see lower fees, and pharmaceutical companies would face reduced demand for dementia treatments. The beneficiaries—elderly patients and the healthcare system—are real, but they’re diffuse. The financial losers would be concentrated and powerful.
The Adoption Barrier: Why Free Isn’t Automatic
Even if hearing aids were free, adoption wouldn’t jump to 100%. There are real barriers beyond cost. Stigma remains substantial: many older adults view hearing aids as a sign of decline or aging, despite wearing bifocals without hesitation. Fitting and adjustment require multiple appointments, and for people with mobility issues, transportation is a challenge. Hearing aid technology has improved dramatically, but cheap or free devices aren’t always equivalent to premium models, and some people with severe or unusual hearing loss configurations need expensive custom solutions. There’s also an adjustment period: hearing aids take weeks to feel natural, and some people abandon them if they don’t experience immediate benefit (which, remember, comes over years, not days). The important limitation revealed by research is that hearing aid effectiveness depends on consistent use.
A 2026 study found hearing aids prevented dementia, but only in people who actually wore them regularly. People who obtained them but didn’t use them regularly saw no dementia protection. This means a free hearing aid program would need to include fitting support, adjustment appointments, ongoing care coordination, and probably replacement programs when devices fail. Some existing programs already do this: the VA provides not just free devices but free fittings and adjustments. The Miracle-Ear Foundation serves people at or below 200% of the federal poverty line with free devices and services. Lions Clubs International’s Affordable Hearing Aid Program provides free or heavily discounted aids. These programs exist, but they’re not universal. The warning: a poorly designed “free hearing aid” program that just mails devices without follow-up support would likely fail to achieve the dementia prevention benefits that research shows are possible.
Real-World Evidence from Existing Assistance Programs
The closest thing we have to a natural experiment in free hearing aids is the VA system, which has provided free hearing aids to eligible veterans for decades. Veterans’ utilization rates are substantially higher than the general population—roughly 50% of veterans with hearing loss use hearing aids, compared to 14% of the general over-50 population. This suggests that cost is indeed a major barrier and that removing it increases adoption. State Medicaid programs provide another data point: coverage varies enormously, and in states with robust Medicaid hearing aid coverage, utilization rates are higher. A person eligible for both Medicare and Medicaid (a “dual eligible”) who lives in a state with good Medicaid hearing aid coverage can get devices essentially free or at minimal cost. Even in these programs, though, adoption isn’t universal—some eligible people still don’t use them due to stigma, transportation, or unfamiliarity with technology.
The Hearing Aid Project, which collects refurbished hearing aids and distributes them at little or no cost, serves as an example of how even basic access increases use. Their model demonstrates that people will use hearing aids if they can get them affordably, even if the devices aren’t brand new. This suggests that a scaled-up free hearing aid program wouldn’t need to provide the most expensive premium devices—mid-range hearing aids, properly fitted and adjusted, can achieve the dementia prevention benefits shown in research. The limitation: existing assistance programs reach only a fraction of eligible seniors. The VA serves roughly 9 million veterans, but there are roughly 40 million Americans age 60 and older, of whom 25% have disabling hearing loss. We have proof of concept that free or low-cost hearing aids work and increase adoption. We don’t yet have a program at the scale needed to study the population-level impact on dementia incidence.
What Happens When Hearing Loss Prevention Becomes a Public Health Priority?
If hearing loss were treated as a dementia prevention priority rather than a personal health choice, the infrastructure would look completely different. Instead of expecting seniors to seek out hearing aids as an optional lifestyle purchase, screening would be automatic: every person turning 60 would get a free hearing test, and anyone with treatable hearing loss would be offered free hearing aids as a public health intervention. This model already works for other prevention: we screen for high blood pressure and cholesterol, and we treat them because they’re risk factors for disease. Hearing loss is at least as modifiable and probably more preventable in its consequences than either of those. A public health approach would also drive innovation: companies would compete on quality and comfort for a large subsidized market rather than on price point for a luxury consumer market. The forward-looking insight is that dementia prevention will likely shift dramatically over the next decade as evidence accumulates and aging populations demand solutions.
Hearing aid technology is already improving—newer models are smaller, more discreet, and easier to adjust. Over-the-counter hearing aids are democratizing access. If policy caught up with evidence, a combined approach—universal screening, free or heavily subsidized hearing aids, integration with primary care—could prevent hundreds of thousands of dementia cases annually. This would happen faster and at lower cost than any pharmaceutical pipeline will deliver. The realistic timeline: getting hearing aids free for seniors through Medicare would require legislative action, which means it depends on political priorities. But the dementia crisis is accelerating (by 2050, the number of people with dementia is projected to triple), and the politics of prevention are shifting. It’s increasingly likely that hearing loss treatment will become recognized as a core dementia prevention strategy within the next 5-10 years.
Conclusion
The case for free hearing aids for seniors as a dementia prevention strategy is overwhelming from both an evidence and economics perspective. The science is clear: hearing loss is the largest modifiable risk factor for dementia, treating it with hearing aids reduces dementia risk by 30% to 60% depending on severity and age, and the research spans hundreds of thousands of people and decades of follow-up. The economics are equally clear: hearing aids cost $2,000 to $4,000; dementia care costs hundreds of thousands. Even a modest improvement in dementia prevention would justify the cost many times over. The barrier isn’t scientific or financial.
It’s that hearing aids are currently treated as a consumer purchase rather than a public health intervention, which means most seniors don’t use them, and the dementia prevention benefit remains largely unrealized. The path forward requires recognizing that hearing loss isn’t a cosmetic concern or a personal inconvenience—it’s a major public health risk factor that can be addressed at a fraction of the cost of treating the dementia it causes. If policymakers made hearing aids free for seniors through Medicare, removed barriers to fitting and adjustment, and integrated hearing loss screening into routine senior care, the impact on dementia prevention would exceed what any drug in development could achieve. The research shows it works. The question is whether we’ll implement it.
